Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06370793
Other study ID # NBU-2024-011
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date July 1, 2018
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source Ningbo University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

In recent years, the prevalence of severe mental disorders in China has continued to grow, and the burden of disease in society has continued to rise. In order to improve the prognosis of patients with severe mental disorders and reduce the risk of disease relapse or readmission, researchers established a cohort based on the Ningbo Mental Health Information System in Ningbo, a sub-provincial city in the southern wing of the Yangtze River Delta of China, with a resident population of more than 9 million, and linked it to the residents' health records, and through the data linkage obtained data on patients in the full cycle of pre-diagnosis, diagnosis, follow-up, disease changes and death, realising full-cycle management of patients with severe mental disorders. Currently, NEED has accumulated data on more than 50,000 patients with severe mental disorders and obtained multi-dimensional longitudinal information through long-term follow-up and data linkage. All diseases follow the World Health Organization International Classification of Diseases 10th Edition (ICD-10) for clinical coding, and available data include baseline demographics, past history, family history, social functioning deficit screening scale scores, risk assessment, and so on and longitudinal health information from electronic health records (EHR), providing a solid data base for future real-world studies.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 57212
Est. completion date December 31, 2026
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Clinical diagnosis of schizophrenia (F20) - Clinical diagnosis of schizo-affective disorder (F25) - Clinical diagnosis of paranoid psychoses (F22) - Clinical diagnosis of bipolar disorder (F30-F31) - Clinical diagnosis of epileptic psychosis (F06.8) - Clinical diagnosis of mental retardation (F70-F79) Exclusion Criteria: - None.

Study Design


Intervention

Other:
Patient with severe mental disorder without intervention
Patients with severe mental disorders identified based on exposures of interest to the study

Locations

Country Name City State
China Ningbo Mental Health Information System Ningbo Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Ningbo University The Affiliated Kangning Hospital of Ningbo University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Risk of circulatory system diseases At least one of the following diagnoses in the electronic health records : Primary hypertension (I10), Cerebral infarction (I63), Transient cerebral ischaemic attacks and related syndromes (G45), Intracerebral haemorrhage (I61), Subarachnoid haemorrhage (I60), Hemorrhagic stroke (I60-I61), Stroke (I60-I64, I69), Pulmonary embolism (I26), Aortic aneurysm and dissection (I71), Cardiovascular disease (I20-I25), Atrial fibrillation (I48), Cardiomyopathy (I42), Peripheral vascular diseases (I73), Myocardial infarction (I21-I22), Heart failure (I50).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of endocrine system diseases At least one of the following diagnoses in the electronic health records : Diabetes mellitus (E10-E14), Thyroid disorder (E00-E05, E61-E69, E07), Gout (E79, M10).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of pulmonary system and allergy diseases At least one of the following diagnoses in the electronic health records : Chronic pulmonary disease (J40-J47), Allergy (J30.1-J30.4, L23, L50.0, T78.0, T78.2, T78.4).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of gastrointestinal system diseases At least one of the following diagnoses in the electronic health records : Ulcer/chronic gastritis (K22.1, K25-K28, K29.3-K29.5), Chronic liver disease (B16-B19, K70, K74, K76.6, I85), Inflammatory bowel disease (K50-K51), Diverticular disease of intestine (K57).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of musculoskeletal system diseases At least one of the following diagnoses in the electronic health records :Connective tissue disorders (M05-M06, M08-M09, M30-M36, D86), Osteoporosis (M80-M82).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of urogenital system diseases At least one of the following diagnoses in the electronic health records : Chronic kidney disease (N03, N11, N18-N19), Prostate disorders (N40).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of hematological system diseases At least one of the following diagnoses in the electronic health records : HIV/AIDS (B20-B24), Anemias (D50-D53, D55-D59, D60-D61, D63-D64).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of cancers Diagnosed with cancer (C00-C43, C45-C97) in electronic health records. Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of neurological system diseases At least one of the following diagnoses in the electronic health records :Vision problem (H40, H25, H54), Hearing problem (H90-H91, H93.1), Migraine (G43), Epilepsy (G40-G41), Parkinson's disease (G20-G22), Multiple sclerosis (G35), Neuropathies (G50-G64).
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
Primary Risk of suicide At least one of the following records in the Ningbo Mental Health Information System: attempted suicide, suicide, death by suicide.
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
Recorded during the study period (2019-2023)
Primary Risk of violence At least one of the following records in the Ningbo Mental Health Information System: causing trouble, causing an accident, committing an offence, injuring another person.
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
Recorded during the study period (2019-2023)
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A